Alercell, Inc. aims to streamline the process for testing of cancer and Leukemia in developing cancer testing technology through very early genetic detection. We imagine a world where testing detects disease before any clinical symptoms.
Alercell leverages AI to develop more precise and targeted biomarkers for the earliest possible detection of cancer. By analyzing extensive patient data, we enhance our understanding of diseases and their evolution over time. Our research is driven by advanced methodologies, including deep learning, machine learning, and other cutting-edge technologies, pushing the boundaries of diagnostic innovation.
Lena Q51 the most advanced Leukemia genetic diagnostic test
